Skip to main content
OpenTrials
Completed

NCT Number: NCT00861757

Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia

This study is a randomized, double-blind, placebo and tamsulosin-controlled, parallel design, multinational study to evaluate the efficacy and safety of Tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign prostatic hyperplasia (BPH).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Benign Prostatic Hyperplasia Genital Diseases Genital Diseases, Male Male Urogenital Diseases Prostatic Diseases Prostatic Hyperplasia Urogenital Diseases

Age range

45 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 3

Primary location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyōgo, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Asian males, with benign prostatic hyperplasia (BPH) for at least 6 months prior to initiation and IPSS score greater than or equal to 13 at the beginning of the treatment
  • Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED) and overactive bladder (OAB) treatments at any time during the study.
  • Have not taken Finasteride or Dutasteride therapy, Anti-androgenic hormone or any other BPH therapy, ED or OAB therapy for specified duration of time prior to the beginning of the treatment

Exclusion criteria

  • Prostate specific antigen (PSA) score beyond acceptable range defined for study at initiation
  • History of urinary retention or lower urinary tract (bladder) stones within 6 months of initiation
  • History of urinary urethral obstruction due to stricture, valves, sclerosis, or tumor at initiation
  • Clinical evidence of prostate cancer at initiation
  • Clinical evidence of any of the bladder or urinary tract conditions, which may affect lower urinary tract symptom at initiation
  • History of cardiac conditions, including Angina requiring certain treatment with nitrates, unstable angina defined for study, positive cardiac stress test before starting the study
  • History of significant central nervous system injuries (including stroke or spinal cord injury within 6 months of initiation)
  • Use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone (LHRH)agonists/antagonists, or anabolic steroids at initiation

Treatment and study plan

Tadalafil

Drug

by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks

Other names: LY450190, Cialis

Placebo

Drug

PO, QD (30 min after meal) for 12 weeks

Tamsulosin

Drug

PO, QD (30 min after meal) for 12 weeks

Primary outcomes

  1. Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks

    Time frame: baseline, 12 weeks

    The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.

Secondary outcomes

  1. Change From Baseline to 12 Weeks in International Prostate Symptom Score (IPSS) Subscore (Storage [Irritative] and Voiding [Obstructive])

    Time frame: baseline, 12 weeks

    IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms); 4 questions of the obstructive score range from 0 to 20. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); 3 questions of the irritative subscore range from 0 to 15. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.

  2. Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks

    Time frame: baseline, 12 weeks

    Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).

    Least Squares Mean values were controlled for Benign Prostatic Hyperplasia severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.

  3. Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks

    Time frame: baseline, 12 weeks

    The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least Squares Mean values were controlled for BPH severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.

  4. Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks

    Time frame: baseline, 12 weeks

    Qmax: defined as the peak urine flow rate (measured in milliliters per second [mL/second] using standard calibrated flowmeter).

    Least Squares Mean values were controlled for Benign Prostatic Hyperplasia (BPH) severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.

  5. Patient Global Impression of Improvement (PGI-I) at Week 12

    Time frame: 12 weeks

    The PGI-I measures the patient's perception of improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).

  6. Clinician Global Impression of Improvement (CGI-I) at Week 12

    Time frame: 12 weeks

    The CGI-I measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).

  7. Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks

    Time frame: baseline, 12 weeks

    Nanograms of PSA per milliliter (ng/mL) of blood.

  8. Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks

    Time frame: baseline, 12 weeks

    The PVR is defined as the volume of urine remaining in the bladder after voiding, estimated by ultrasound.

  9. Change From Baseline in Blood Pressure (Sitting) at 12 Weeks

    Time frame: baseline, 12 weeks

  10. Change From Baseline in Blood Pressure (Standing) at 12 Weeks

    Time frame: baseline, 12 weeks

  11. Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks

    Time frame: baseline, 12 weeks

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase 3, Randomized, Double Blind, Placebo and Tamsulosin Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil Once a Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Mar 13, 2009
Registry last updated
Jun 28, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.